NASDAQ : XLO
Xilio Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 8.03 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 52.84M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 51.65M |
| Enterprise Value | -78.08M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 6.58M |
| Shares Outstanding | 6.58M |
| Shares Change (YoY) | +77.75% |
| Shares Change (QoQ) | +13.79% |
| Owned by Insiders (%) | 8.17% |
| Owned by Institutions (%) | 26.29% |
| Float | 3.40M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.80 |
| Forward PS | 1.23 |
| PB Ratio | 0.73 |
| P/TBV Ratio | 0.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.25 |
| Quick Ratio | 4.15 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -55.03% |
| Return on Assets (ROA) | -13.61% |
| Return on Invested Capital (ROIC) | -42.07% |
| Return on Capital Employed (ROCE) | -26.13% |
| Weighted Average Cost of Capital (WACC) | 3.19% |
| Revenue Per Employee | $843,316 |
| Profits Per Employee | -$287,224 |
| Employee Count | 76 |
| Asset Turnover | 0.44 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.12 |
| 52-Week Price Change | -29.53% |
| 50-Day Moving Average | 8.77 |
| 200-Day Moving Average | 8.49 |
| Relative Strength Index (RSI) | 39.58 |
| Average Volume (20 Days) | 14,901 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 400,316 |
| Short Previous Month | 410,050 |
| Short % of Shares Out | 6.08% |
| Short % of Float | 11.77% |
| Short Ratio (days to cover) | 39.90 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 64.09M |
| Gross Profit | 53.30M |
| Operating Income | -31.37M |
| Pretax Income | -21.83M |
| Net Income | -21.83M |
| EBITDA | -30.03M |
| EBIT | -31.37M |
| Loss Per Share | -$3.32 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 136.04M |
| Total Debt | 6.30M |
| Net Cash | 129.74M |
| Net Cash Per Share | $19.72 |
| Equity (Book Value) | 72.26M |
| Book Value Per Share | 10.98 |
| Working Capital | 111.27M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -60.60M |
| Capital Expenditures | -670,000 |
| Depreciation & Amortization | 1.34M |
| Net Borrowing | n/a |
| Free Cash Flow | -61.27M |
| FCF Per Share | -$9.31 |
Margins
| Measure | Value |
|---|
| Gross Margin | 83.16% |
| Operating Margin | -48.94% |
| Pretax Margin | -34.06% |
| Profit Margin | -34.06% |
| EBITDA Margin | -46.85% |
| EBIT Margin | -48.94% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -77.75% |
| Shareholder Yield | -77.75% |
| Earnings Yield | -42.26% |
| FCF Yield | -119.07% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $18.00 |
| Price Target Difference | 129.30% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | -45.23% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Mar 16, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:14 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -3.03 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |